PHILADELPHIA, Aug. 30, 2021 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL, an internally ...
Please provide your email address to receive an email when new articles are posted on . Tacrolimus alone had a dose-response relationship with achieving complete renal response in SLE. Combination ...
Please provide your email address to receive an email when new articles are posted on . In a real-world retrospective study, researchers found mycophenolate mofetil treatment to be safe and effective ...
Review the side-effects of Mycophenolate Mofetil as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...
Children with frequently relapsing or steroid-dependent nephrotic syndrome had a significantly longer relapse-free survival period with tacrolimus than with mycophenolate mofetil. Relapse-free ...
Background: The Mycophenolate Steroids Sparing (MYSS) study showed that, when combined with ciclosporin microemulsion, mycophenolate mofetil is not superior to azathioprine in preventing acute ...
† One patient had MMF as an initial treatment. ‡ In the study TAC and MMF were used alone or in combination. §In total, 17 patients were initially treated with MMF and steroids. ¶ Females represented ...
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), CellCept for oral suspension, 200 mg/m; of Roche Palo Alto, LLC, it added. The approval bolsters the ...
The addition of mycophenolate mofetil (MMF) to a glucocorticoid as a first-line treatment for immune thrombocytopenia (ITP) resulted in greater responses and a reduced risk of relapse or refractory ...
Triple-drug immunosuppression regimens including mycophenolate mofetil, taken for ≥6 months are associated with reduced rates of LAR; further studies are needed to define optimal immunosuppression ...
Tacrolimus + mycophenolate mofetil & steroids: Safe, effective in preventing acute cardiac rejection
Initial findings of an immunosuppressant combination study in de novo cardiac transplant recipients presented today at the 24th annual meeting of the International Society for Heart and Lung ...
Substantial evidence exists that patients with scleroderma have immune dysfunction and autoimmunity, and several studies support the use of immunosuppressive treatment in these patients. Nihtyanova et ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results